Fatty Liver Disease is a broad description of conditions in which excess fat accumulates within liver cells. Hepatic fat accumulation can arise from different causes, so the term does not identify a single disease mechanism. Metabolic dysfunction-associated steatotic liver disease, commonly abbreviated MASLD, is the modern terminology used for liver steatosis associated with metabolic risk factors and has replaced much use of the older term nonalcoholic fatty liver disease.
Alcohol-associated liver disease is another major cause of hepatic steatosis and can coexist with metabolic risk factors. NIDDK describes fatty liver in the context of both metabolic dysfunction and alcohol-associated disease and notes that fat accumulation may occur without substantial injury or may accompany inflammation and liver damage.
Fatty Liver Disease exists along a spectrum. Simple steatosis means excess fat is present without the defining degree of inflammatory liver injury associated with steatohepatitis. Metabolic dysfunction-associated steatohepatitis, or MASH, refers to steatosis accompanied by inflammation and hepatocellular injury and can lead to fibrosis. Fibrosis represents accumulation of scar tissue produced during chronic liver injury, and progressive fibrosis can eventually result in cirrhosis. Not everyone with hepatic steatosis develops progressive fibrosis, and the amount of visible fat alone does not determine long-term outcome. The clinically important question is therefore not merely whether fat exists in the liver, but whether there is associated injury, fibrosis and ongoing risk of liver-related complications.
Metabolic Fatty Liver Disease is strongly associated with conditions involving insulin resistance and altered energy metabolism. Risk is increased by overweight or obesity, type 2 diabetes, abnormal blood lipids, metabolic syndrome and related metabolic abnormalities. The underlying biology includes increased delivery of fatty acids to the liver, altered de novo lipogenesis, impaired lipid oxidation and changes in insulin signalling, although the relative contribution of each pathway differs among individuals. Genetics also influence susceptibility and disease progression. Diet, physical activity and broader metabolic health can affect hepatic fat accumulation. Importantly, body size alone does not determine whether fatty liver is present or whether it will progress, because metabolic risk and genetic susceptibility can occur across a range of body compositions.
Fatty Liver Disease is frequently clinically silent. Many people have no symptoms even when substantial steatosis or fibrosis is present, while some experience fatigue or discomfort in the upper right abdomen. Liver enzymes may be normal in some people with significant disease, so routine blood tests cannot reliably exclude clinically important liver pathology. Evaluation can include medical history, physical examination, blood tests and imaging. Imaging can identify hepatic fat, while non-invasive fibrosis assessment can estimate the likelihood of significant scarring. Liver biopsy provides direct histological information and can distinguish certain forms of steatohepatitis, but it is invasive and is not required for every person. Diagnostic strategies therefore combine clinical risk factors with biochemical and imaging information.
Progression of Fatty Liver Disease depends heavily on fibrosis and the presence of continuing liver injury. Advanced fibrosis and cirrhosis can lead to portal hypertension, ascites, hepatic encephalopathy, variceal bleeding and liver failure. Cirrhosis also increases the risk of hepatocellular carcinoma. Fatty liver is additionally associated with substantial cardiovascular and metabolic risk, meaning its importance extends beyond the liver itself. The presence of hepatic steatosis can therefore serve as a marker of broader metabolic dysfunction. However, progression is heterogeneous: some individuals remain stable for many years, while others develop progressive fibrosis. Genetics, metabolic disease, age, alcohol exposure and other factors can modify risk.
Management of Fatty Liver Disease depends on its cause and severity. For metabolic disease, gradual weight reduction when appropriate, healthier dietary patterns and physical activity can reduce hepatic fat and may improve inflammation and fibrosis. NIDDK reports that losing at least 3 to 5 percent of body weight can reduce liver fat, while larger reductions may be needed to improve inflammation and fibrosis in appropriate patients. Physical activity can provide benefit even without weight loss. Management also involves addressing diabetes, abnormal lipids, blood pressure and other cardiovascular risk factors. Alcohol exposure should be assessed because metabolic and alcohol-related causes can overlap, making simplistic classification based on a single factor unreliable.
Terminology has changed substantially as understanding of the disease has developed. The older terms nonalcoholic fatty liver disease and nonalcoholic steatohepatitis emphasised exclusion of heavy alcohol consumption, whereas newer terminology such as MASLD and MASH emphasises positive metabolic criteria. This change reflects recognition that metabolic and alcohol-related factors can coexist and that a binary alcohol-versus-metabolic model can oversimplify real patients. Fatty Liver Disease should also be distinguished from alcoholic hepatitis, viral hepatitis and other causes of hepatic inflammation. Steatosis is a description of fat accumulation, whereas hepatitis refers to inflammation and fibrosis refers to scarring; these processes can occur together but are not synonymous.
The broader significance of Fatty Liver Disease lies in its position at the intersection of hepatology, metabolism, nutrition, cardiovascular medicine and the gut-liver axis. The liver integrates glucose, lipid and amino-acid metabolism and receives blood containing nutrients and microbial products from the intestine. Alterations in the Gut Microbiome and Intestinal Permeability are therefore being investigated as potential contributors to metabolic liver disease, although they do not replace established metabolic explanations.
Research increasingly focuses on identifying people at greatest risk of progressive fibrosis and developing non-invasive methods for monitoring disease. The key conceptual distinction is between the common finding of hepatic fat and the smaller but clinically important subset in whom chronic liver injury and fibrosis progress towards advanced liver disease.
